- Tricyclic kinase inhibitors
-
The invention belongs to the technical field of medicines, and particularly relates to tricyclic DNA-PK kinase inhibitor compounds as shown in a general formula (I), pharmaceutically acceptable salts or isomers thereof, a pharmaceutical composition and prepartion containing the compounds, the pharmaceutically acceptable salts or the isomers thereof, a method for preparing the compound and the pharmaceutically acceptable salts or isomers thereof, and uses of the compounds and pharmaceutically acceptable salts or isomers thereof.
- -
-
Paragraph 0244-0247
(2021/10/27)
-
- MERTK DEGRADERS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same.
- -
-
Paragraph 00683
(2020/01/31)
-
- Preparation method of 5-bromo-2-chloro-7H-pyrrolo [2, 3-d] pyrimidine
-
The invention discloses a preparation method of 5-bromo-2-chloro-7H-pyrrolo[2, 3-b] pyridine. According to the method, 2,4-chloro-7H-pyrrolo[2, 3-d] pyrimidine is used as a starting raw material, in the presence of zinc powder and acetic acid, selective d
- -
-
Paragraph 0008; 0025-0033; 0039-0040; 0042-0045; 0051
(2020/05/08)
-
- CYCLIN-DEPENDENT KINASE INHIBITORS
-
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
- -
-
Page/Page column 260-261
(2020/07/15)
-
- Preparation method of MER/FLT3 dual-inhibitor intermediate
-
The invention discloses a preparation method of an MER/FLT3 dual-inhibitor intermediate, namely, trans-4(5-bromo-2-chloro-7H-pyrrole[2,3-d] pyrimidine-7-yl)-cyclohexanol. The preparation method comprises steps as follows: a compound II is taken as a raw m
- -
-
Paragraph 0048; 0069; 0088 - 0091
(2018/02/04)
-